Company Overview and News

 
SD / Sandridge Energy Inc. 8-K

20h sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
SD / Sandridge Energy Inc. 8-K (Current Report)

20h sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
BRIEF-SandRidge Energy Announces Board Changes And Nomination Of Directors For Election At 2018 Shareholder Meeting

2018-04-18 reuters
* SANDRIDGE ENERGY ANNOUNCES BOARD OF DIRECTOR CHANGES AND NOMINATION OF DIRECTORS FOR ELECTION AT 2018 SHAREHOLDER MEETING
Upvote Downvote

1
Icahn nominates five to replace entire SandRidge board

2018-04-16 channelnewsasia
Billionaire activist investor Carl Icahn nominated a five-person slate of his employees and business associates to replace the SandRidge Energy Inc board of directors on Monday, escalating his fight for control of the U.S. shale oil producer.
Upvote Downvote

 
UPDATE 1-Icahn says to nominate five members to SandRidge board

2018-04-16 reuters
(Reuters) - Activist investor Carl Icahn, who is seeking to push SandRidge Energy to sell itself, said on Monday that he plans to nominate five members to U.S. shale oil producer’s board.
Upvote Downvote

 
SD / Sandridge Energy Inc. / ICAHN CARL C - null (Activist Investment)

2018-04-16 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHED
Upvote Downvote

1
SD / Sandridge Energy Inc. / ICAHN CARL C - null (Activist Investment)

2018-04-16 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHED
Upvote Downvote

 
SD / Sandridge Energy Inc. null

2018-04-16 sec.gov
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a)
Upvote Downvote

 
April 13 Natural Gas Weekly: Storage Forecast And Update On Supply/Demand Balance

2018-04-15 seekingalpha
We currently expect EIA to report a draw of 24 bcf next week, which should be the last draw before an injection season begins.
Upvote Downvote

1
Energy XXI Finally Hit Bottom

2018-04-13 seekingalpha
The oil price rise has given the company breathing room for all the necessary improvements noted. Whether management has the time needed to achieve all this is another matter. Oil prices can be volatile.
Upvote Downvote

1
SD / Sandridge Energy Inc. / FIR TREE INC. - SANDRIDGE ENERGY, INC. (Activist Investment)

2018-04-09 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
SD / Sandridge Energy Inc. / FIR TREE INC. - SANDRIDGE ENERGY, INC. (Activist Investment)

2018-04-09 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
SD / Sandridge Energy Inc. 8-K

2018-04-09 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
SD / Sandridge Energy Inc. 8-K (Current Report)

2018-04-09 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
SandRidge says to evaluate buyout offers, including Icahn's

2018-04-09 channelnewsasia
SandRidge Energy Inc, which is in the middle of a proxy fight with top shareholder Carl Icahn, said on Monday it would evaluate buyout offers, including one from Icahn.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 80007P869